Wegovy Pill UK: Cost, Approval & When to Expect It
Googling ‘Wegovy pill UK’ at 11 pm? We understand, and you’re not alone. It’s all over social media, especially if you follow influencers from the US.
It is a pill version of semaglutide, the same molecule that’s in the Wegovy injection. It was launched in the United States in January 2026.
The question everyone in the UK is asking is: when do we get ours?
Honestly, it’ll take time.
Here’s the full picture on what’s happening with the approval, what we know about cost, who might be eligible, and what you can actually do right now if you’re ready to start.
Is the Wegovy Pill Approved in the UK Yet?
No. Here’s why -
MHRA vs FDA: Two Completely Separate Review Processes
The US FDA approving a drug does not automatically mean it’s approved in the UK whilst the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) runs entirely independent reviews.
While the FDA approval of the Wegovy pill on 22 December 2025 acts as a strong signal for the MHRA review, both yet follow separate processes, with separate timelines and decisions.
Current UK Regulatory Status
Novo Nordisk submitted the Wegovy pill to the MHRA in late 2025. As of June 2026, the application is still under review. Approval is yet to be awaited, and so is the launch date.
This means:
• The Wegovy pill cannot legally be prescribed in the UK
• No UK pharmacy can legally dispense it
• Any product sold online as the ‘Wegovy pill’ in the UK right now is unlicensed and potentially counterfeit or unsafe
Estimated UK Availability: What Medical Sources Are Saying
Based on the regulatory timeline, here’s what we feel:
• MHRA decision: We expect it in late 2026, based on the typical review timeline from submission
• Private prescription availability: If and when approved, private clinics could begin offering the pill from late 2026 or early 2027. It’ll be similar to how injectable Wegovy entered the private market before the NHS
• NHS availability: For drugs to be accessible through the NHS, a separate NICE approval is required, which typically takes about 6–12 months. So you can expect the Wegovy pill through the NHS in early 2027 or probably later.
Please note: these timelines are estimates based on current information. Regulatory decisions can move faster or slower than expected. We’ll update this article as official news lands.
How Much Will the Wegovy Pill Cost in the UK?
We don’t know yet. And that means, no one knows yet. The price for the Wegovy pill has not been set yet because it is not yet approved here. But if we were to guess -
What We Know From the US Launch
The Wegovy pill launched in the United States in January 2026 through Novo Nordisk’s NovoCare Pharmacy programme. Here’s how they priced it there:
• Self-pay (no insurance): from approximately $149/month (~£110) at the lowest dose
• Higher doses: up to $299/month (~£220)
This is significantly lower than the US list price for injectable Wegovy, which has historically exceeded $1,300/month. But this time, Novo Nordisk appears to have strategically priced the pill to compete on accessibility.
You can probably guess a ballpark price for the UK market from this.
Oral vs Injectable Wegovy: Expected Cost Difference
Injectable Wegovy currently costs £130–£295/month privately in the UK, depending on dose. Most analysts, including us, expect the pill to be priced below the injection. Here’s why:
• The pill doesn’t require refrigeration. So, no cold chain storage and distribution costs
• Manufacturing a tablet is usually less complex than producing a pre-filled injectable pen
• Novo Nordisk has signalled that the pill is partly designed to improve accessibility
If UK pricing mirrors the US approach, the pill could land around £100–£150/month at lower doses. Again, this is all speculation. We’ll know only once the official news is out.
Will the Wegovy Pill Be Available on the NHS?
Not any time soon. Here are the steps that need to happen before the Wegovy pill is given access to the NHS:
For context, even the injectable version of Wegovy, which has been approved in the UK since 2022, is still only available through specialist NHS weight management services with long waiting lists in most areas. You can expect the same journey for the pill.
So, if you’re waiting for the NHS to prescribe the Wegovy pill, we will bet on GTA VI launch before that.
And if that’s the case, the next question naturally would be -
Will buying the Wegovy pill privately make sense?
When comparing, it’ll be unfair to only look at the medication price. A good private programme can offer you much more than just a prescription. Things that are important for your smooth journey and safe transformation. They include -
• Clinical assessment before prescribing
• Blood tests (thyroid function, liver, HbA1c, cholesterol)
• Ongoing clinician-led dose reviews
• Side effect support and an accessible clinical team
• Repeat blood monitoring at 6 and 12 months
Where to Get the Wegovy Pill in the UK?
Expected Access Routes After Approval
We are guessing that the route should be the same for the pill as it was for the injection. And if that’s the case, here’s what you can expect -
• Private online clinics - The fastest route. Online providers like SheMed that are GPhC-registered and CQC-regulated will likely offer the pill shortly after MHRA approval, following the same clinical assessment process as the injection
• High street pharmacies with prescribing services: Boots, Lloyds Pharmacy, and others already offer injectable GLP-1s via online consultation. The pill would likely be added similarly
• NHS GP: Once NICE guidance is in place, which will be much later than private availability. It will also be subject to local commissioning decisions
• NHS specialist services: This will be the last route to open up, and the most restricted in terms of eligibility
Warning: What to Avoid Right Now
Do not buy anything sold as the ‘Wegovy pill’ in the UK right now. The MHRA has not approved it. Any product claiming to be the oral Wegovy tablet is unlicensed. It hasn’t been assessed for safety, purity, or effectiveness by any UK regulator. The MHRA seized nearly 20 million doses (worth £45 million) of illegal weight loss drugs in 2025.
The same black market that sells counterfeit injections has already started going after the pill. Always verify GPhC registration at pharmacyregulation.org before purchasing any medication online.
Know more about how the black market for skinny jabs work
Who Will Be Eligible for the Wegovy Pill in the UK?
We don’t know yet. We can be certain once the MHRA and NICE review is done. But based on how the injection is currently prescribed, here’s what we can reasonably expect.
NICE Eligibility Criteria: What the Current Framework Looks Like
This is what the eligibility works in the UK for injectable Wegovy and Mounjaro -
• Private prescription: BMI 30+ (or BMI 27+ with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea)
• NHS via specialist services (NICE TA875): BMI 35+ with at least one comorbidity, referred to a specialist weight management service
• NHS GP prescribing (expected in 2026–27): BMI 35–39.9 with weight-related comorbidities, with eligibility widening over the coming years
The pill will almost certainly follow the same framework. It’s basically the same drug, with the same clinical evidence base. So, Novo Nordisk will naturally seek the same indications.
Specific Considerations for Women: PMOS, Menopause, and Thyroid Medication
This is the part that we feel is the most important.
PMOS:
GLP-1 medications are not licensed specifically for PMOS (formally known as Polycystic Ovarian Syndrome or PCOS for short) in the UK, but if you suffer from PMOS and also meet the BMI criteria, you can get them prescribed for weight management.
Weight loss is known to significantly improve PMOS symptoms like cycle regularity, androgen levels, and insulin sensitivity. If you have PMOS and a BMI of 27+ with metabolic comorbidities, there’s a high chance you meet the private eligibility criteria right now.
Perimenopause and menopause:
Weight gain around perimenopause is common. And this is the kind of gain that doesn’t really go away despite a diet and regular exercise because of its hormonal nature that affects metabolism and fat distribution.
Post-hoc analyses from OASIS 4 specifically looked at menopausal status and found that women across all stages, pre-, peri-, and post-menopausal, lost 15–18% of body weight on average.
The pill, just like the injection, works on the biology rather than just behaviour.
Thyroid:
If you’re taking levothyroxine (thyroid medication), you might need to plan it properly. The Wegovy pill requires a strict 30-minute fast, and levothyroxine also requires an empty stomach. So you’ll just have to plan both accordingly. But don’t worry. Your prescriber will help you work this out. Just make sure you disclose all medications during your clinical assessment.
What about Switching From Injectable Wegovy or Mounjaro?
If you’re already on the injection and want to switch to the pill when it’s available, you will need a new clinical assessment. But that doesn’t mean starting from scratch again. It’s just about disclosing all details about your current treatment to your prescriber.
The most important thing to know here is: switching from the injection to the pill is not a direct dose-for-dose swap. The pill has a higher rate of nausea and vomiting during the early weeks. Your prescriber will need to determine an appropriate oral starting dose.
What Can You Access Right Now While You Wait?
Basically, Wegovy pill’s whole selling point is that it’s the same molecule as the injection. So, if you’re only looking for semaglutide and are not that afraid of injections, you’ve got 0 reasons to wait.
Injectable Wegovy – Your answer
Wegovy injection is fully licensed in the UK for weight management and is available privately from £130/month. It contains the same active ingredient, semaglutide and works on the same GLP-1 mechanism.
The trial results show 14.9% weight loss at the 2.4mg dose (STEP 1), and 20.7% with the newly approved 7.2mg dose (STEP UP, MHRA approved January 2026).
If you have a genuine needle phobia, then we understand the wait. But, if it’s something else, like the convenience, the no-fridge appeal, or simply just curiosity about the new format, starting with the injection now and switching to the pill later might not be the worst idea.
Mounjaro: Another good option
If you think Wegovy’s results are not appealing enough, you can try the double-action Mounjaro. It contains the active ingredient tirzepatide and works on both GLP-1 and GIP. It is currently the highest-performing licensed weight loss medication in the UK. It produces an average of 22.5% weight loss at 72 weeks at the 15mg dose (SURMOUNT-1). It’s available privately from £149/month.
Want to further understand the difference between Wegovy and Mounjaro?
We’ve written an entire article on it. Click here! (Link to our existing article – Mounjaro vs Wegovy)
What Happens With SheMed When the Pill Arrives
We’re keeping a close eye on the MHRA review. When the Wegovy pill is approved, and we’re able to prescribe it, we’ll notify members who have expressed interest. In the meantime, if you’re ready to start treatment now, the injection offers the same clinical foundation.
Frequently Asked Questions
When will the Wegovy pill be available in the UK?
The MHRA decision is expected later in 2026, following Novo Nordisk’s submission in late 2025. Once approved, private clinics could begin offering the pill from late 2026 or early 2027. NHS access would take longer, most probably in 2027, after the NICE review.
How much will the Wegovy pill cost in the UK?
Wegovy pill price in the UK has not been confirmed yet. The pill launched in the US at around $149/month (~£110) self-pay for the lowest dose. Price in the UK is expected to be in a similar range, lower than the current injectable Wegovy costs (£130–£295/month).
Can I buy the Wegovy pill online in the UK now?
No, and you shouldn’t try to. The Wegovy pill is not licensed in the UK. Any product being sold online as the ‘Wegovy pill’ is unlicensed and potentially counterfeit or dangerous. The MHRA warns against purchasing prescription medications from unregulated online sources. Always check GPhC registration at pharmacyregulation.org.
Is there a pill alternative to Wegovy available today?
Rybelsus (oral semaglutide, 3–14mg) is the only oral semaglutide currently licensed in the UK, but it’s licensed for type 2 diabetes only, not weight loss. Orlistat and MySimba are one of two oral medications currently NHS-licensed for obesity, but it works differently and produces far lower average weight loss (around 3–5%). Neither is the same product as the higher-dose oral semaglutide designed for weight management.
Will the NHS prescribe the Wegovy pill?
Mostly yes, but not anytime soon. The first step is MHRA approval, then a NICE technology appraisal, then NHS commissioning guidance, and then local Integrated Care Board rollout. Each step takes time. The realistic timeline is 2027, and that too only for patients meeting strict eligibility criteria.
Sources & Further Reading
1. MHRA — GLP-1 Medicines for Weight Loss and Diabetes: What You Need to Know (GOV.UK, 2026)
2. MHRA — Updated Guidance for Semaglutide Prescribers and Patients (GOV.UK, February 2026)
3. NICE TA875 — Semaglutide for Weight Management
4. NICE TA1026 — Tirzepatide (Mounjaro) for Managing Overweight and Obesity
5. Wharton S et al. — OASIS 4: Oral Semaglutide 25mg. NEJM, 2025
6. SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (NEJM, 2022)
7. NHS — Obesity: Treatment Overview
8. MHRA Yellow Card — Report a Side Effect
9. GPhC — Check a Pharmacy Register
10. Source: FDA — Wegovy oral semaglutide approval (December 2025)
11. Source: MHRA — How medicines are approved in the UK
12. Source: MHRA — GLP-1 Medicines for Weight Loss and Diabetes (GOV.UK, updated 2026)
13. Source: Medino.com — Wegovy Cost Per Month UK (2026 Guide)
14. Source: MHRA — Wegovy 7.2mg approval (January 2026)
The content on the SheMed blog is provided for general informational and educational purposes only. While SheMed provides professional weight loss services and strives to ensure the information shared is accurate and up to date, we make no representations or guarantees as to its accuracy, completeness, or timeliness. This content should not be taken as personal medical advice or a substitute for consultation with a qualified healthcare provider. Always speak with your doctor or licensed medical professional about your individual health or medical needs before starting any new treatment or programme. Never disregard or delay seeking professional medical advice because of something you have read on this site. SheMed is not responsible for any actions you may take based on the information provided in this blog.
Related Articles
